TrialAnnals of hematology2018

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.

Martin Griesshammer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.